Razuprotafib - EyePoint Pharmaceuticals
Alternative Names: AKB-9778; EYP-2301Latest Information Update: 28 Jul 2022
At a glance
- Originator Procter & Gamble
- Developer Aadi Bioscience; Akebia Therapeutics; Duke University; Harvard Medical School; Johns Hopkins University School of Medicine; Massachusetts General Hospital; Massachusetts Institute of Technology; Max Planck Institute for Molecular Biomedicine; Medical Technology Enterprise Consortium; New York University; Quantum Leap Healthcare Collaborative
- Class Amides; Antineoplastics; Carbamates; Eye disorder therapies; Small molecules; Sulfonic acids; Thiazoles; Thiophenes
- Mechanism of Action Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors; TIE-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic macular oedema; Diabetic retinopathy; Ocular hypertension; Open-angle glaucoma; Retinal vein occlusion; SARS-CoV-2 acute respiratory disease
- No development reported Age-related macular degeneration; Breast cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Open-angle-glaucoma in USA (Ophthalmic, Drops)
- 26 Aug 2021 Aadi Bioscience has merged with Aerpio Pharmaceuticals to form Aadi Bioscience
- 11 Mar 2021 Aerpio Pharmaceuticals discontinues the phase II RESCUE trial in SARS-COV-2 acute respiratory disease in USA due to challenges associated with recruiting and monitoring patients (NCT04511650)